Here's some of what is coming soon to NeurologyLive® this week.
|Slideshows|June 22, 2017
Update on Migraine and Parkinson Disease: 3 New Studies
Author(s)Mark L. Fuerst
New studies shed light on the potential role of monoclonal antibodies in migraine prophylaxis and in Parkinson disease and on a common genetic pathway shared by PD and autoimmune diseases.
Advertisement
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
A migraine forecasting model achieved 91% precision using app data, but the study did not test whether next-day predictions improve care.
A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.
Here's some of what is coming soon to NeurologyLive® this week.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Extends Relutrigine Review, Delays PDUFA to December
2
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
3
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
4
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
5